Detection of Cell-Free DNA and Gene-Specific Methylation in Blood Plasma of Patients with Renal and Colon Cancer
DOI:
https://doi.org/10.15407/scin8.06.060Keywords:
cell-free DNA, renal cancer, colon cancer, methyl-specific PCR, tumor marker genes.Abstract
Gene-specific methylation and concentration of cell-free DNA in blood can be important tools for the early diagnosis of cancer. Here, we have shown that total cell-free DNA levels were higher in patients with renal and colon cancer compared to healthy individuals. The results indicated that cellfree DNA can be used for detection of hypermethylation of cancer marker genes. CpG islands of LRRC3B, APC and FHIT genes were hypermethylated in 33,3 %; 27,8 % and 33,3 % of patients with renal cancer and in 14,3 %; 28,5 % and 19 % of patients with colon cancer, respectively. Hypermethylation of LRRC3B, APC and FHIT was not detected in cell-free DNA of healthy individuals. We have proposed the methods for quantitative analysis of cell-free DNA in blood plasma and detection of the methylation of marker genes, which could be useful for diagnostics of cancer.
References
Garcia J.A., Rini B.I. Recent progress in the management of advanced renal cell carcinoma. C.A. Cancer. J. Clin. 2007. V. 57, No. 2. P. 112-125.
https://doi.org/10.3322/canjclin.57.2.112
Rynditch A., Pekarsky Y., Schnittger S. et al. Leukemia breakpoint region in 3q21 is gene rich . Gene. 1997. V. 193, No. 1. P. 49-57.
https://doi.org/10.1016/S0378-1119(97)00076-0
Pekarsky Y., Rynditch A., Wieser R. et al. Activation of a novel gene in 3q21 and identification of intergenic transcripts with EVI1 in leukaemia . Cancer. Research. 1997. V. 57, No. 18. P. 3914-3919.
Kashuba V.I., Skripkina I.Ja., Saraev D.V. i dr. Ispol'zovanie NotI-mikrochipov dlja identifikacii izmenenij v lokusah genov, potencial'no uchastvujushhih v razvitii raka shejki matki . Ukr. Biokhim. Zh. 2006. T. 78, No. 2. S. 49-56 [in Russian].
Skrypkina I.Ja., Kashuba V.I., Gordyjuk V.V. ta in. Identyfikacija zmin v lokusah geniv, jaki potencijno zadijani v rozvytku raku nyrok, za dopomogoju novoi' tehnologii' NotI-mikrochypiv . Dopovidi akademii' nauk Ukrai'ny. 2006. No. 11. S. 188-192 [in Ukrainian].
Gerashchenko G.V., Gordiyuk V.V., Skrypkina I.Y. et al. Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer. Ukr.Biokhim. Zh. 2009. V. 81, No. 4. P. 81-87.
Leon S.A., Shapiro B., Sklaroff D.M. and Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977. V. 37, No. 3. P. 646-650.
Chang H.W., Goodman S.N., Singer G. et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as dia g nostic tests for cancer . J Natl. Cancer Inst. 2002. V. 94. P. 1697-1703.
https://doi.org/10.1093/jnci/94.22.1697
Ellinger J., Bastian P.J., Haan K.I. et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2008. V. 122, No. 1. P. 138-143.
https://doi.org/10.1002/ijc.23057
Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker A critical appraisal of the literature. Clinica. Chimica. Acta. 2010. V. 411. P. 1611-1624.
https://doi.org/10.1016/j.cca.2010.07.032
Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer A survey. Biochimica et Biophy sica Acta. 2007. V. 1775. P. 181-232.
https://doi.org/10.1016/j.bbcan.2006.10.001
Vlassov V.V., Laktionov P.P., Rykova E.Y. Circulating nucleic acids as a potential source for cancer biomarkers. Curr. Mol. Med. 2010. V. 10. P. 142-165.
https://doi.org/10.2174/156652410790963295
Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer. 2011. V. 11, No. 6. P. 426-437.
https://doi.org/10.1038/nrc3066
Czeiger D., Shaked G., Eini H. et al. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am. J. Clin. Pathol. 2011. V. 135, No. 22. P. 64-70.
https://doi.org/10.1309/AJCP4RK2IHVKTTZV
Martino M., de Klatte T., Haitel A. and Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2012. V. 18, No. 1. P. 82-90.
https://doi.org/10.1002/cncr.26254
Hauser S., Zahalka T., Ellinger J. et al. Cell-free Circulating DNA: Diagnostic Value in Patients with Renal Cell Cancer. Anticancer Research. 2010. V. 30. P. 2785-2790.
Tian X.Q., Zhang Y., Sun D. et al. Epigenetic silencing of LRRC3B in colorectal cancer. Scand J Gastroenterol. 2009. V. 44, No. 1. P. 79-84.
https://doi.org/10.1080/00365520802400834
Kim M., Kim J.H., Jang H.R. et al. LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer. Cancer Res. 2008. V. 68, No. 17. P. 7147-7155.
https://doi.org/10.1158/0008-5472.CAN-08-0667
Kondratov A.G., Stoliar L.A., Kvasha S.M. et al. Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas. Mol. Med. Report. 2012. V. 5, No. 2. P. 509-512.
Pekarsky Y., Garrison P.N., Palamarchuk A. et al. Fhit is a physiological target of the protein kinase. Src. Proc Natl Acad. Sci. USA. 2004. V. 101, No. 11. P. 3775-3779.
https://doi.org/10.1073/pnas.0400481101
Kvasha S., Gordiyuk V., Kondratov A. et al. Hyper methyla tion of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett. 2008. V. 265, No. 2. P. 250-257.
https://doi.org/10.1016/j.canlet.2008.02.036
Brock M.V., Hooker C.M., Ota-Machida E. et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 2008. V. 358, No. 11. P. 1118-1128.
https://doi.org/10.1056/NEJMoa0706550
Rowan A.J., Lamlum H., Ilyas M. et al. APC mutations in sporadic colorectal tumors: A mutational «hotspot» and interdependence of the «two hits». Proc. Natl. Acad. Sci. USA. 2000. V. 97, No. 7. P. 3352-3357.
